Assess whether pediatric studies are necessary or waivable (4a10b7)

Situation

In a mid-size sponsor after a complete response letter, biosimilar analytical similarity report is the evidence after a CMO 483 that maps to the NDA CMC module. 505(b)(2) development lead has to pick Pediatric studies are necessary or Waivable for this Pharma & Life Sciences Clinical and Evidence Strategy close using biosimilar analytical similarity report.

Decision

505(b)(2) development lead in a mid-size sponsor after a complete response letter must choose Pediatric studies are necessary / Waivable using biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• A CMO 483 that maps to the NDA CMC module is noise around an already-controlled Clinical and Evidence Strategy process in a mid-size sponsor after a complete response letter, given biosimilar analytical similarity report.
• A CMO 483 that maps to the NDA CMC module is the event in biosimilar analytical similarity report that forces Pediatric studies are necessary for 505(b)(2) development lead under Pharma & Life Sciences.
• Biosimilar analytical similarity report shows a one-file miss after a CMO 483 that maps to the NDA CMC module, not a Clinical and Evidence Strategy program failure.
• Biosimilar analytical similarity report cannot decide pediatric studies are necessary yet after a CMO 483 that maps to the NDA CMC module; hold is the only Pharma & Life Sciences close a mid-size sponsor after a complete response letter can defend.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• Check whether biosimilar analytical similarity report supports the labeled claim 505(b)(2) development lead would keep.
• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read biosimilar analytical similarity report against a CMO 483 that maps to the NDA CMC module and write the one fact that would move pediatric studies are necessary for 505(b)(2) development lead.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module). If biosimilar analytical similarity report cannot force a Pharma & Life Sciences label under Clinical and Evidence Strategy, stop. If biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module cannot support Pediatric studies are necessary versus Waivable on this Pharma & Life Sciences Clinical and Evidence Strategy close, 505(b)(2) development lead must state the unresolved clinical or safety evidence requirement explicitly.